NCT04796402Unknown4 期
A Pragmatic Eight Week Phase IV Study of Bamlanivimab/LY-CoV555 for Emergency Passive Immunity Against COVID-19
Fraser Health1 个研究点 分布在 1 个国家目标入组 576 人开始时间: 2021年3月17日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 576
- 试验地点
- 1
- 主要终点
- Any incidence of admission to hospital for >24 hours in the 28 days following first positive test for SARS-CoV2.
研究概览
简要总结
The purpose of this research is to test whether a new medication called bamlanivimab is safe and effective at reducing the need for hospitalization due to COVID-19.
详细描述
The study aims to examine the effectiveness of adding bamlanivimab provided by COVID-19 Clinics to standard of care on the incidence of hospitalization for high-risk patients infected with SARS-CoV2. Furthermore, we aim to test the effect on the following secondary outcomes: mortality and health-related quality of life and patients' satisfaction with care. We will also assess the recruitment rate from the three primary strategies for rapid identification and consent of eligible patients. The data from this study will inform clinical decisions about the use of bamlanivimab in high risk COVID-19 patients and the operational requirements necessary for research in passive immunity therapeutics.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age at the time of SARS-CoV2 test:
- •Age 55-64 and 1 or more of:
- •i. BMI>35, ii. chronic kidney disease, iii. diabetes mellitus, iv. immunosuppressive disease v. current immunosuppressive treatment vi. hypertension vii. coronary artery disease viii. chronic lung disease
- •c. Age 18-54 and 1 or more of: i. BMI>35 ii. chronic kidney disease iii. diabetes mellitus iv. immunosuppressive disease v. current immunosuppressive treatment
- •Disease Characteristics:
- •Not hospitalized
- •Sample collection for first SARS-CoV2 test positive within 3 days prior to consent.
- •One or more mild COVID-19 symptoms and within 10 days from onset
- •i. Fever ii. Cough iii. Sore throat iv. Malaise v. Headache vi. Muscle pain vii. Gastrointestinal symptoms viii. Shortness of breath with/without exertion
- •Study Procedures:
- •Resident of British Columbia
- •Understand and agree to planned study procedures
- •Ability and Willingness to Provide Informed Consent:
- •The participant will provide informed consent by telephone
排除标准
- •Medical Conditions
- •Allergies to any of the components used in the formulation of the bamlanivimab
- •Hospitalization or expected to need hospitalization in the next 24 hours at the time of recruitment for COVID-19
- •Suspected or proven infection other than COVID-19 that in the opinion of the clinicians could pose a risk to study inclusion
- •Any co-morbidity considered life-threatening in <28 days, or requiring surgery in <7 days.
- •Any serious disease, condition or disorder that in the opinion of the clinicians should preclude participation.
- •Require oxygen therapy due to COVID-19
- •Require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.
- •Weighs < 40 kg
- •History of vaccination against SARS-CoV2
- •History of convalescent plasma or IVIG therapy within 3 months of first SARS-CoV2 viral determination positive
- •History of previous SARS-CoV2 infection
- •History of participation in any clinical study involving an investigational intervention within 30 days or 5 half-lives of the previous intervention, whichever is longer.
- •Unable to achieve informed consent for any reason
- •Known Pregnancy
- •Actively breast-feeding.
结局指标
主要结局
Any incidence of admission to hospital for >24 hours in the 28 days following first positive test for SARS-CoV2.
时间窗: 0 - 28 days following first positive test for COVID 19
次要结局
- Overall satisfaction with participation in research.(6 months post-treatment)
- Mortality following first positive test for SARS-CoV2.(28 days, 3 month and 6 months post-treatment)
- Health-related quality of life assessment.(Screening and 6 months post-treatment)
- Any incidence of admission to hospital for >24 hours following first positive test for SARS-CoV2.(0 - 28 days following first positive test for COVID-19)
- Incidence and types of adverse reactions including anaphylaxis.(Treatment day and up to 6 months post-treatment)
- Recruitment rate.(Upto 8 weeks from day of first patient recruited to day of last patient recruited)
- Hospitalization by age and comorbidities.(Treatment day and up to 6 months post-treatment)
- Type and frequency of viral variants in patients receiving bamlanivimab.(Up to 8 weeks from day of first patient recruited to day of last patient recruited)
研究者
Gregory Haljan, MD
Principal Investigator
Fraser Health
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast CancerNeoplasms, BreastNCT00105950GlaxoSmithKline126
已完成
2 期
Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast CancerNeoplasms, BreastNCT00111787GlaxoSmithKline49
撤回
1 期
A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune DiseaseNCT06413511GlaxoSmithKline16
招募中
1 期
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL AmyloidosisAL AmyloidosisAmyloidosisNCT05145816University of Texas Southwestern Medical Center37
已完成
1 期
A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)Healthy ParticipantsNCT05684289Bristol-Myers Squibb61